SEC Form 4 · accession 0000899243-16-025940
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roberto Guerciolini
Officer — See Remarks
Period of report
Jul 28, 2016
Accepted (ET)
Jul 29, 2016 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jul 28, 2016 | M | 5,000 | $2.47 | A | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $2.47 | Jul 28, 2016 | M | 5,000 | D | — | Mar 22, 2025 | Ordinary Shares | 5,000 | 103,617 | D |
Explanation of responses
- F1The option represented a right to purchase a total of 108,617 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter.
Remarks
Senior Vice President, Head of Early Development